BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mezones-Holguin E, Gamboa-Cardenas RV, Sanchez-Felix G, Chávez-Corrales J, Helguero-Santin LM, Laban Seminario LM, Burela-Prado PA, Castro-Reyes MM, Fiestas F. Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Patients Receiving Infliximab: A Systematic Review in the Context of Decision-Making From a Latin-American Country. Front Pharmacol 2019;10:1010. [PMID: 31798442 DOI: 10.3389/fphar.2019.01010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Alawneh K, Al-mistarehi A, Qandeel A, Jaber R, Alomari S, Kheirallah KA, Saadeh C. The Safety and Effectiveness of Infliximab Biosimilar in Managing Rheumatoid Arthritis: A Real-Life Experience from Jordan. International Journal of Clinical Practice 2022;2022:1-12. [DOI: 10.1155/2022/3406783] [Reference Citation Analysis]
2 Campello CP, Lima ELS, Fernandes RSM, Porto M, Muniz MTC. TNF-α levels and presence of SNP-308G/A of TNF-α gene in temporomandibular disorder patients. Dental Press J Orthod 2022;27:e2220159. [PMID: 35239943 DOI: 10.1590/2177-6709.27.1.e2220159.oar] [Reference Citation Analysis]
3 Choquette D, Chan J, Bardi M, Whiskin C, Torani G, Smith BK, Sihota A. Monitoring the transition of patients on biologics in rheumatoid arthritis: Consensus guidance for pharmacists. Pharm Pract (Granada) 2021;19:2377. [PMID: 34621449 DOI: 10.18549/PharmPract.2021.3.2377] [Reference Citation Analysis]
4 Abidin AZ, Snoswell CL, Shafiee Hanjani L, Callaghan G, Edmonds M. Infliximab switching from reference product to biosimilar: a review of evidence regarding the clinical efficacy, safety profile and immunogenicity. J Pharm Pract Res 2021;51:358-73. [DOI: 10.1002/jppr.1754] [Reference Citation Analysis]
5 Bonek K, Roszkowski L, Massalska M, Maslinski W, Ciechomska M. Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. Cells 2021;10:323. [PMID: 33557301 DOI: 10.3390/cells10020323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Miler M, Nikolac Gabaj N, Grazio S, Vahtarić A, Vrtarić A, Grubišić F, Skala Kavanagh H, Doko Vajdić I, Vrkić N. Lower concentration of vitamin D is associated with lower DAS28 and VAS-pain scores in patients with inflammatory rheumatic diseases treated with infliximab: a pilot study. Rheumatol Int 2020;40:1455-61. [PMID: 32462255 DOI: 10.1007/s00296-020-04607-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]